Ondansetron for Acute Gastroenteritis

Introduction to Ondansetron

Ondansetron can be used to treat vomiting associated with a stomach bug (acute gastroenteritis) in children over 4 years of age and adults, but should only be considered after adequate hydration has been established and should not replace proper fluid and electrolyte therapy, as recommended by the Infectious Diseases Society of America 1

Ondansetron is a serotonin 5-HT3 receptor antagonist that blocks serotonin receptors in the chemoreceptor trigger zone and inhibits vagal afferents, thereby improving nausea and vomiting, according to the American Gastroenterological Association 2
It has been shown to reduce vomiting in children with acute gastroenteritis and can reduce the immediate need for hospitalization or intravenous rehydration, as reported by the Infectious Diseases Society of America 1

For children >4 years of age and adolescents: Ondansetron may be given to facilitate tolerance of oral rehydration in acute gastroenteritis associated with vomiting, as recommended by the Infectious Diseases Society of America 1, 3
For adults: Typical dosing is 4-8 mg taken 2-3 times daily, according to the American Gastroenterological Association 2

Hydration status must be addressed first: Antiemetic treatment should not substitute for proper fluid and electrolyte therapy, as emphasized by the Infectious Diseases Society of America 1, 3
Age restrictions: Guidelines specifically recommend against routine use in children under 4 years of age, as stated by the Infectious Diseases Society of America 1, 4

QT interval prolongation is a rare but serious potential side effect that should be considered, particularly in patients with cardiac conditions, according to the American Gastroenterological Association 2

Oral rehydration therapy remains the cornerstone of treatment for acute gastroenteritis, as recommended by the Infectious Diseases Society of America 1
For adults with watery diarrhea without fever, loperamide may be considered for symptom management, as suggested by the Infectious Diseases Society of America 1, 4